(s)-tianeptine and use in treating disorders and conditions associated with peroxisome proliferator-activated receptor

HK40137457APending Publication Date: 2026-09-11TONIX PHARMA LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026126210
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-24
Filing Date
2026-07-16
Publication Date
2026-09-11

Smart Images

  • Figure 00000204_0000
    Figure 00000204_0000
  • Figure 00000205_0000
    Figure 00000205_0000
  • Figure 00000206_0000
    Figure 00000206_0000
Patent Text Reader

Abstract

The present disclosure provides the (S)-enantiomer of 7-(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ylamino)heptanoic acid ((S)-tianeptine) and the (S)-enantiomer of deuterated tianeptine (11-D-(S)-tianeptine), both being characterized as comprising no more than 2%, or no more than about 0.1%, of the corresponding (R)-enantiomer. The present disclosure further provides salts, amides, esters, co-crystals, crystals, analogs and pharmaceutical compositions thereof and methods of using the (S)-enantiomers and those compounds and compositions for treating diseases, disorders or conditions of the CNS as well as diseases, conditions and disorders associated with altered activity of, exacerbated by or modulated by the peroxisome proliferator-activated receptors (PPAR)-β / δ and / or PPAR-γ, while minimizing or eliminating the potential for opioid abuse. The present disclosure also provides methods of producing the (S)-enantiomer and 11-D-(S)-enantiomer and related compounds of this disclosure.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This disclosure provides (S)-enantiomers of 7-(3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo[c,f][1,2]thiazo-11-ylamino)heptanic acid ((S)-tiaptine) and (S)-enantiomers of deuterated tiaptine (11-D-(S)-tiaptine), characterized in that both contain no more than 2% or no more than about 0.1% of the corresponding (R)-enantiomer. The invention further provides salts, amides, esters, cocrystals, crystals, analogs, and pharmaceutical compositions thereof of (S)-enantiomers, compounds, and compositions thereof, as well as methods of treating central nervous system diseases, disorders, or conditions using (S)-enantiomers, compounds, and compositions thereof, and methods of treating diseases, disorders, and conditions associated with alterations, exacerbations, or modulation of peroxisome proliferation-activating receptor (PPAR)-β / δ and / or PPAR-γ activity, while minimizing or eliminating the possibility of opioid abuse. This invention also provides methods for preparing the (S)-enantiomers and 11-D-(S)-enantiomers of this invention and related compounds.

Claims

Attorney Docket No.: 104545-0096-WO1 CLAIMS What is claimed is:

1. The (S)-enantiomer of 7-(3-chloro-6-methyl-5,5-dioxido-6,11- dihydrodibenzo[c,f][1,2]thiazepin-11-ylamino)heptanoic acid ((S)-enantiomer of tianeptine) of the general Formula (Ia), the zwitterion thereof of Formula (Ib) or a pharmaceutically acceptable salt of the (S)-enantiomer, or a mixture of two or more of these species, wherein the (S)-enantiomer, zwitterion or pharmaceutically acceptable salt are characterized by comprising ≤ about 2% of the (R)-enantiomer of tianeptine, the zwitterion thereof or a pharmaceutically acceptable salt of the (R)-enantiomer:Formula (Ia) Formula (Ib).

2. The (S)-enantiomer according to claim 1, wherein the (S)-enantiomer, the zwitterion or pharmaceutically acceptable salt of the (S)-enantiomer are characterized by comprising ≤ about 0.1% of the (R)-enantiomer of tianeptine or the zwitterion thereof or a pharmaceutically acceptable salt of that enantiomer.

3. A pharmaceutically acceptable salt of the (S)-enantiomer according to claim 1 or 2, wherein the pharmaceutically acceptable salt is (S)-tianeptine benzenesulfonate (1:1), (S)-tianeptine fumarate (1:1), (S)-tianeptine fumarate (2:1), (S)-tianeptine hippurate (1:1), (S)-tianeptine maleate (1:1), (S)-tianeptine maleate (2:1), (S)-tianeptine p- toluenesulfonate (1:1), (S)-tianeptine orotate (1:1), (S)-tianeptine camphorsulfonate (1:1), (S)-tianeptine N-acetyl-L-tyrosinate (1:1), (S)-tianeptine polisterix, (S)- tianeptine: L-DBTA (2:1), (S)-tianeptine sodium,(S)-tianeptine oxalate or (S)- tianeptine hemi-oxalate (2:1).Attorney Docket No.: 104545-0096-WO1 4. The pharmaceutically acceptable salt of the (S)-enantiomer according to claim 3, wherein the pharmaceutically acceptable salt is (S)-tianeptine hemi-oxalate (2:1).

5. A zwitterion comprising the zwitterion of the (S)-enantiomer according to claim 1 or 2.

6. A co-crystal of the (S)-enantiomer according to claim 1 or 2, wherein the (S)- enantiomer or the zwitterion thereof forms a complex with L-tyrosine, L-tryptophan, L-phenylalanine, or another L-amino acid.

7. An ester of the (S)-enantiomer according to claim 1 or 2, wherein the ester of the (S)- enantiomer or pharmaceutically acceptable salt thereof is characterized by comprising ≤ about 2% of the ester of the (R)-enantiomer or pharmaceutically acceptable salt thereof.

8. The ester of the (S)-enantiomer according to claim 7, wherein the ester of the (S)- enantiomer or pharmaceutically acceptable salt thereof is characterized by comprising ≤ about 0.1% of the ester of the (R)-enantiomer or pharmaceutically acceptable salt thereof.

9. An amide of the (S)-enantiomer according to claim 1 or 2, wherein the amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof is characterized by comprising ≤ about 2% of the amide of the (R)-enantiomer or pharmaceutically acceptable salt thereof.

10. The amide of the (S)-enantiomer according to claim 9, wherein the amide of the (S)- enantiomer or pharmaceutically acceptable salt thereof is characterized by comprising ≤ about 0.1% of the amide of the (R)-enantiomer or pharmaceutically acceptable salt thereof.

11. The (S)-enantiomer of deuterated 7-((3-chloro-6-methyl-5,5-dioxido-6,11- dihydrodibenzo[c,f][1,2]thiazepin-11-yl-11-d)amino)heptanoic acid (11-D-(S)- enantiomer of tianeptine) of the general Formula (IIa) or the zwitterion thereof ofAttorney Docket No.: 104545-0096-WO1 Formula (IIb) or a pharmaceutically acceptable salt of the 11-D-(S)-enantiomer, or a mixture of two or more of these species, wherein deuterium replaces hydrogen at the 11- position, and wherein the 11-D-(S)-enantiomer or zwitterion or pharmaceutically acceptable salt thereof are characterized by comprising ≤ about 2% of the 11-D-(R)- enantiomer of tianeptine or the zwitterion thereof or a pharmaceutically acceptable salt of the 11-D-(R)-enantiomer:Formula (IIa) Formula (IIb).

12. The (S)-enantiomer according to claim 11, wherein the 11-D-(S)-enantiomer, the zwitterion or pharmaceutically acceptable salt of the 11-D-(S)-enantiomer are characterized by comprising ≤ about 0.1% of the 11-D-(R)-enantiomer of tianeptine or the zwitterion thereof or a pharmaceutically acceptable salt of that enantiomer.

13. The (S)-enantiomer according to claim 11 or 12, wherein the 11-D-(S)-enantiomer or the zwitterion or pharmaceutically acceptable salt of the 11-D-(S)-enantiomer is characterized by reduced racemization at position 11 as compared to the (S)- enantiomer of tianeptine or the zwitterion or a pharmaceutically acceptable salt of that enantiomer.

14. A pharmaceutically acceptable salt of the 11-D-(S)-enantiomer according to any one of claims 11-13, wherein the pharmaceutically acceptable salt is 11-D-(S)-tianeptine benzenesulfonate (1:1), 11-D-(S)-tianeptine fumarate (1:1), 11-D-(S)-tianeptine fumarate (2:1), 11-D-(S)-tianeptine hippurate (1:1), 11-D-(S)-tianeptine maleate (1:1), 11-D-(S)-tianeptine maleate (2:1), 11-D-(S)-tianeptine p-toluenesulfonate (1:1), 11-D-(S)-tianeptine orotate (1:1), 11-D-(S)-tianeptine camphorsulfonate (1:1), 11-D-(S)-tianeptine N-acetyl-L-tyrosinate (1:1), 11-D-(S)-tianeptine polisterix, 11-D-Attorney Docket No.: 104545-0096-WO1 (S)-tianeptine: L-DBTA (2:1), 11-D-(S)-tianeptine sodium, 11-D-(S)-tianeptine oxalate or 11-D-(S)-tianeptine hemi-oxalate (2:1).

15. The pharmaceutically acceptable salt of the 11-D-(S)-enantiomer according to claim 14, wherein the pharmaceutically acceptable salt is 11-D-(S)-tianeptine hemi-oxalate (2:1).

16. A zwitterion comprising the zwitterion of the 11-D-(S)-enantiomer according to any one of claims 11-13.

17. A co-crystal of the 11-D-(S)-enantiomer according to any one of claims 11-13, wherein the 11-D-(S)-enantiomer or the zwitterion thereof forms a complex with L- tyrosine, L-tryptophan, L-phenylalanine, or another L-amino acid.

18. An ester of the (S)-enantiomer according to any one of claims 11-13, wherein the ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof is characterized by comprising ≤ about 2% of the ester of the 11-D-(R)-enantiomer or pharmaceutically acceptable salt thereof.

19. The ester of the (S)-enantiomer according to claim 18, wherein the ester of the 11-D- (S)-enantiomer or pharmaceutically acceptable salt thereof is characterized by comprising ≤ about 0.1% of the ester of the 11-D-(R)-enantiomer or pharmaceutically acceptable salt thereof.

20. An amide of the (S)-enantiomer according to any one of claims 11-13, wherein the amide of the 11-D-(S)-enantiomer or the pharmaceutically acceptable salt thereof is characterized by comprising ≤ about 2% of the amide of the 11-D-(R)-enantiomer or the pharmaceutically acceptable salt thereof.

21. The amide of the (S)-enantiomer according to claim 20, wherein the amide of the 11- D-(S)-enantiomer or pharmaceutically acceptable salt thereof is characterized by comprising ≤ about 0.1% of the amide of the 11-D-(R)-enantiomer or pharmaceutically acceptable salt thereof.Attorney Docket No.: 104545-0096-WO1 22. A pharmaceutically acceptable acid salt of the (S)-enantiomer or the 11-D-(S)- enantiomer according to any one of claims 1, 2 or 11-13, wherein the nitrogen atom in the sidechain attached to Carbon-11 (C-11) is 100% protonated, the 100% protonated salt being less sensitive to air oxidation in solid or solution forms when compared to the (S)-enantiomer, 11-D-(S)-enantiomer, the zwitterion of either or the sodium salts of either.

23. A pharmaceutical composition comprising the (S)-enantiomer of tianeptine, the zwitterion thereof, or a pharmaceutically acceptable salt of the (S)-enantiomer, or a co-crystal of the (S)-enantiomer or zwitterion thereof according to any one of claims 1-6, or an ester of the (S)-enantiomer or a pharmaceutically acceptable salt thereof according to claim 7 or 8, or an amide of the (S)-enantiomer or a pharmaceutically acceptable salt thereof according to claim 9 or 10 and a pharmaceutically acceptable carrier, diluent, or excipient, wherein the composition comprises ≤ about 2% of the (R)-enantiomer of tianeptine, the zwitterion thereof or a pharmaceutically acceptable salt of the (R)-enantiomer, or a co-crystal of the (R)-enantiomer or zwitterion thereof, or the ester of the (R)-enantiomer or a pharmaceutically acceptable salt thereof, or the amide of the (R)-enantiomer or a pharmaceutically acceptable salt thereof.

24. The pharmaceutical composition of claim 23, wherein the pharmaceutical composition comprises ≤ about 0.1% of the (R)-enantiomer of tianeptine, the zwitterion thereof or pharmaceutically acceptable salt of the (R)-enantiomer, or co- crystal of the (R)-enantiomer or zwitterion thereof, or the ester of the (R)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the (R)-enantiomer or pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition comprising the 11-D-(S)-enantiomer of tianeptine, the zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(S)-enantiomer, or a co-crystal of the 11-D-(S)-enantiomer or zwitterion thereof according to any one of claims 11-17, or an ester of the 11-D-(S)-enantiomer or a pharmaceutically acceptable salt thereof according to claim 18 or 19, or an amide of the 11-D-(S)- enantiomer or a pharmaceutically acceptable salt thereof according to claim 20 or 21 and a pharmaceutically acceptable carrier, diluent, or excipient, wherein the composition comprises ≤ about 2% of the 11-D-(R)-enantiomer of tianeptine, theAttorney Docket No.: 104545-0096-WO1 zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(R)-enantiomer, or a co-crystal of the 11-D-(R)-enantiomer or zwitterion thereof, or an ester of the 11- D-(R)-enantiomer or a pharmaceutically acceptable salt thereof, or an amide of the 11-D-(R)-enantiomer or a pharmaceutically acceptable salt thereof.

26. The pharmaceutical composition according to claim 25, wherein the pharmaceutical composition comprises ≤ about 0.1% of the 11-D-(R)-enantiomer of tianeptine, the zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(R)-enantiomer, or co-crystal of the 11-D-(R)-enantiomer or zwitterion thereof, or the ester of the (R)- enantiomer or pharmaceutically acceptable salt thereof, or an amide of the 11-D-(R)- enantiomer or pharmaceutically acceptable salt thereof.

27. The pharmaceutical composition according to any one of claims 23-26, wherein the composition is in the form of a tablet, a thin film, a powder, a caplet, a capsule, a soft gel, a suppository, a nasal spray, an oral spray or a lung spray.

28. The pharmaceutical composition according to any one of claims 23-26, wherein the composition is formulated for immediate release, controlled release, sustained release, extended release, or slow release of the (S)-enantiomer or the 11-D-(S)-enantiomer, or the zwitterion or an ester or an amide of either, or a pharmaceutically acceptable salt of either, or a co-crystal of the (S)-enantiomer or the 11-D-(S)-enantiomer or the zwitterion of either.

29. A pharmaceutical composition comprising a mixture of two or more pharmaceutically acceptable salts or co-crystals of the (S)-enantiomer or the 11-D-(S)-enantiomer according to any one of claims 23-26, wherein the mixture is characterized by an enhanced extended release when administered orally as compared to administering a composition comprising a single pharmaceutically acceptable salt or co-crystal of the (S)-enantiomer or the 11-D-(S)-enantiomer according to any one of claims 23-26.

30. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with altered activity of peroxisome proliferator-activated receptor (PPAR)-β / δ and / or PPAR-γ and one or more associated symptoms thereof, comprising administering to a subject in need or at risk thereof a therapeuticallyAttorney Docket No.: 104545-0096-WO1 effective amount of the (S)-enantiomer, the zwitterion thereof, or a pharmaceutically acceptable salt of the (S)-enantiomer, or a co-crystal of the (S)-enantiomer or the zwitterion thereof, or an ester of the (S)-enantiomer or a pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or a pharmaceutically acceptable salt thereof according to any one of claims 1-10 and 22, or a pharmaceutical composition according to any one of claims 23, 24 and 27-29.

31. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with altered activity of peroxisome proliferator-activated receptor (PPAR)-β / δ and / or PPAR-γ and one or more associated symptoms thereof, comprising administering to a subject in need or at risk thereof a therapeutically effective amount of the 11-D-(S)-enantiomer, the zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(S)-enantiomer or a co-crystal of the 11- D-(S)-enantiomer or the zwitterion thereof, or an ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 11-22, or a pharmaceutical composition according to any one of claims 25-29.

32. The method according to claim 30 or 31, wherein the disease, disorder or condition is selected from the group consisting of a central nervous system (CNS) disorder, inflammatory disease, autoimmune disease, infectious illness, a hearing loss condition, ocular disease, musculoskeletal disease, metabolic disease, mitochondrial disease, hypertriglyceridemia, cancer, menopause and chronic overlapping pain conditions (COPCs), and psychological, physical, metabolic or hormonal stress and COPCs.

33. The method according to claim 32, wherein the CNS disorder is selected from the group consisting of a mood disorder, a trauma and stress-related disorder, an anxiety disorder, obsessive-compulsive disorder, a neurodegenerative or neuroinflammatory disorder, a neurodevelopmental disorder, a leukodystrophy and CNS oxidative stress.

34. The method according to claim 33, wherein the mood disorder is a depressive disorder, a bipolar disorder, or a substance-induced disorder.Attorney Docket No.: 104545-0096-WO1 35. The method according to claim 34, wherein the depressive disorder is major depressive disorder (MDD).

36. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with altered activity of peroxisome proliferator-activated receptor (PPAR)-β / δ and / or PPAR-γ and one or more associated symptoms thereof, in a subject who has experienced high stress, comprising administering to the subject a therapeutically effective amount of the (S)-enantiomer, the zwitterion thereof, or a pharmaceutically acceptable salt of the (S)-enantiomer, or a co-crystal of the (S)- enantiomer or the zwitterion thereof, or an ester of the (S)-enantiomer or a pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or a pharmaceutically acceptable salt thereof according to any one of claims 1-10 and 22, or a pharmaceutical composition according to any one of claims 23, 24 or 27-29.

37. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with altered activity of peroxisome proliferator-activated receptor (PPAR)-β / δ and / or PPAR-γ and one or more associated symptoms thereof, in a subject who has experienced high stress, comprising administering to the subject a therapeutically effective amount of the 11-D-(S)-enantiomer, the zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(S)-enantiomer or a co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or an ester of the 11-D-(S)-enantiomer or a pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or a pharmaceutically acceptable salt thereof according to any one of claims 11-22, or a pharmaceutical composition according to any one of claims 25-29.

38. The method according to claim 36 or 37, wherein the stress is caused by adversity early in life or by childhood trauma.

39. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with altered activity of peroxisome proliferator-activated receptor (PPAR)-β / δ and / or PPAR-γ and one or more associated symptoms thereof, while reducing µ-opioid receptor agonism associated with treatment with racemic tianeptine, comprising administering to a subject in need or at risk thereof a therapeutically effective amount of the (S)-enantiomer, the zwitterion thereof, or aAttorney Docket No.: 104545-0096-WO1 pharmaceutically acceptable salt of the (S)-enantiomer, or a co-crystal of the (S)- enantiomer or the zwitterion thereof, or an ester of the (S)-enantiomer or a pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or a pharmaceutically acceptable salt thereof according to any one of claims 1-10 and 22, or a pharmaceutical composition according to any one of claims 23, 24 and 27-29.

40. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with altered activity of peroxisome proliferator-activated receptor (PPAR)-β / δ and / or PPAR-γ and one or more associated symptoms thereof, while reducing µ-opioid receptor agonism associated with treatment with racemic tianeptine, comprising administering to a subject in need or at risk thereof a therapeutically effective amount of the 11-D-(S)-enantiomer or a co-crystal of the 11- D-(S)-enantiomer or the zwitterion thereof, or an ester of the 11-D-(S)-enantiomer or a pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or a pharmaceutically acceptable salt thereof according to any one of claims 11-22, or a pharmaceutical composition according to any one of claims 25-29.

41. The method according to any one of claims 30-40 or 59, wherein the (S)-enantiomer, the zwitterion or ester thereof, the pharmaceutically acceptable salt of the (S)- enantiomer, the co-crystal of the (S)-enantiomer or the zwitterion thereof, or the ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof or the 11-D-(S)- enantiomer, the zwitterion or ester thereof, the pharmaceutically acceptable salt of the 11-D-(S)-enantiomer, the co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or the ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof or the pharmaceutical composition is administered one or more times daily.

42. The method according to any one of claims 30-40 or 59, wherein the (S)-enantiomer, the zwitterion or ester thereof, the pharmaceutically acceptable salt of the (S)- enantiomer, the co-crystal of the (S)-enantiomer or the zwitterion thereof, or the ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof or the 11-D-(S)- enantiomer, the zwitterion or ester thereof, the pharmaceutically acceptable salt of theAttorney Docket No.: 104545-0096-WO1 11-D-(S)-enantiomer, the co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or the ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition is administered parenterally, orally, sublingually, buccally, inhalationally, palatially, transdermally, rectally, or vaginally.

43. The method according to any one of claims 30-42 or 59, wherein the (S)-enantiomer, the zwitterion or ester thereof, the pharmaceutically acceptable salt of the (S)- enantiomer, the co-crystal of the (S)-enantiomer or the zwitterion thereof, or the ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof or the 11-D-(S)- enantiomer, the zwitterion or ester thereof, the pharmaceutically acceptable salt of the 11-D-(S)-enantiomer, the co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or the ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof or the pharmaceutical composition is administered sequentially or concurrently with one or more additional therapeutic agents selected from the group consisting of an antidepressant, an anticonvulsant, an anti-anxiety agent, an antipsychotic agent, a cholinesterase inhibitor, an N-methyl-D-aspartate (NMDA) receptor antagonist, a 5HT2 modulator, a corticosteroid, an anti-amyloid agent, an anti-tau agent and a chemotherapeutic agent.

44. The method according to any one of claims 30-42 or 59, wherein the (S)-enantiomer, the zwitterion or ester thereof, the pharmaceutically acceptable salt of the (S)- enantiomer, the co-crystal of the (S)-enantiomer or the zwitterion thereof, or the ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof or the 11-D-(S)- enantiomer, the zwitterion or ester thereof, the pharmaceutically acceptable salt of the 11-D-(S)-enantiomer, the co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or the ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof or the pharmaceutical composition is administered as part of a treatment regime also including psychotherapeutic intervention.Attorney Docket No.: 104545-0096-WO1 45. A method of reducing the potential racemization of the (S)-enantiomer, the zwitterion thereof, the pharmaceutically acceptable salt of the (S)-enantiomer, the co-crystal of the (S)-enantiomer or the zwitterion thereof, or the ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 1-10 and 22, comprising the step of deuterating the (S)-enantiomer, the zwitterion thereof, the pharmaceutically acceptable salt of the (S)-enantiomer, the co-crystal of the (S)- enantiomer or the zwitterion thereof, or the ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or the amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof at position C-11.

46. A method of producing the (S)-enantiomer of tianeptine according to claim 1 or 2, said method comprising the steps of: (i) resolving a racemic or other mixture of the (S)- and (R)-enantiomers of a chiral amine tianeptine intermediate, which mixtures are characterized by ≥0.1% of the (R)-enantiomer of the chiral amine tianeptine intermediate by enantioselective crystallization using a conformer selective for the (S)- enantiomer in a solvent mixture to produce an (S)-amine tianeptine intermediate:(S)-enantiomer-selective-conformer, the (S)-amine tianeptine intermediate:(S)-enantiomer-selective-conformer being crystallized from the solvent mixture, and being characterized in that it comprises ≤2% of the (R)- amine tianeptine intermediate: (R)-enantiomer-selective-conformer; (ii) reacting the (S)-amine tianeptine intermediate:(S)-enantiomer-selective- conformer with a 7-bromoheptanoate alkyl ester to produce an (S)-tianeptine alkyl ester intermediate:(S)-enantiomer-selective-conformer; (iii) reacting the (S)-tianeptine alkyl ester intermediate:(S)-enantiomer-selective- conformer with a base to produce the (S)-tianeptine alkyl ester intermediate and (iv) saponifying the (S)-tianeptine alkyl ester intermediate to produce the (S)- enantiomer of tianeptine, which tianeptine comprises ≤2% of the (R) enantiomer of tianeptine.

47. The method according to embodiment 46, wherein the (S)-enantiomer of tianeptine is characterized by ≤0.1% of the (R)-enantiomer of tianeptine.Attorney Docket No.: 104545-0096-WO1 48. A method of producing the 11-D-(S)-tianeptine according to claim 11 or 12, said method comprising the steps of: (i) resolving a racemic or other mixture of the (S)- and (R)-enantiomers of a chiral amine 11-D-tianeptine intermediate, which mixtures are characterized by ≥0.1% of the (R)-enantiomer of the chiral amine 11-D-tianeptine intermediate by enantioselective crystallization using a conformer selective for the (S)-enantiomer in a solvent mixture to produce an (S)-amine 11-D- tianeptine intermediate:(S)-enantiomer-selective-conformer, the (S)-amine 11- D-tianeptine intermediate:(S)-enantiomer-selective-conformer being crystallized from the solvent mixture, and being characterized in that it comprises ≤2% of the (R)-amine 11-D-tianeptine intermediate:(R)- enantiomer-selective-conformer -conformer; (ii) reacting the (S)-amine 11-D-tianeptine intermediate:(S)-enantiomer-selective- conformer with a 7-bromoheptanoate alkyl ester to produce an 11-D-(S)- tianeptine alkyl ester intermediate:(S)-enantiomer-selective-conformer; (iii) reacting the 11-D-(S)-tianeptine alkyl ester intermediate:(S)-enantiomer- selective-conformer with a base to produce the 11-D-(S)-tianeptine alkyl ester intermediate and (iv) saponifying the 11-D-(S)-tianeptine alkyl ester intermediate to produce the 11- D-(S)-enantiomer of tianeptine, which 11-D-(S)-tianeptine comprises ≤2% of the (R) enantiomer of 11-D-tianeptine.

49. The method according to claim 48, wherein the (S)-enantiomer of 11-D-tianeptine is characterized by ≤0.1% of the (R)-enantiomer of 11-D-tianeptine.

50. A method of producing the (S)-enantiomer of tianeptine or zwitterion thereof according to claim 1 or 2, said method comprising the steps of: (i) resolving a racemic or other mixture of the (S)- and (R)-enantiomers of a tianeptine alkyl ester, which mixtures are characterized by ≥0.1% of the (R)- enantiomer of a tianeptine alkyl ester by enantioselective crystallization using conformer selective for the (R)-enantiomer in a solvent mixture to produce an (R)-tianeptine alkyl ester:(R)-enantiomer-selective-conformer and an (S)- tianeptine alkyl ester:(R)-enantiomer-selective-conformer, crystallizing andAttorney Docket No.: 104545-0096-WO1 separating the (R)-tianeptine alkyl ester from the solvent mixture, the (S)- tianeptine alkyl ester remaining in the solvent mixture and being characterized in that it comprises ≤2% of the (R)-tianeptine alkyl ester; (ii) hydrolyzing the (S)-tianeptine alkyl ester:(R)-enantiomer-selective-conformer with a strong acid to produce the (S)-tianeptine acid salt, which tianeptine acid salt comprises ≤2% of the (R)-tianeptine acid salt; and (iii) neutralizing the (S)-tianeptine acid salt with a base to produce the zwitterion of the (S)-enantiomer of tianeptine.

51. A method of producing the 11-D-(S)-enantiomer or zwitterion thereof according to claim 11 or 12, said method comprising the steps of: (i) resolving a racemic or other mixture of the (S)- and (R)-enantiomers of an 11- D-tianeptine alkyl ester, which mixtures are characterized by ≥0.1% of the (R)-enantiomer of an 11-D-tianeptine alkyl ester by enantioselective crystallization using a conformer selective for the (R)-enantiomer in a solvent mixture to produce an 11-D-(R)-tianeptine alkyl ester:(R)-enantiomer- selective-conformer and an 11-D-(S)-tianeptine alkyl ester:(R)-enantiomer- selective-conformer, crystallizing and separating the 11-D-(R)-tianeptine alkyl ester from the solvent mixture, the 11-D-(S)-tianeptine alkyl ester remaining in the solvent mixture and being characterized in that it comprises ≤2% of the 11-D-(R)-tianeptine alkyl ester; (ii) hydrolyzing the 11-D-(S)-tianeptine alkyl ester:(R)-enantiomer-selective- conformer with a strong acid to produce the 11-D-(S)-tianeptine acid salt, which 11-D-tianeptine acid salt comprises ≤2% of the 11-D-(R)-tianeptine acid salt; and (iii) neutralizing the 11-D-(S)-tianeptine acid salt with a base to produce the zwitterion of the 11-D-(S)-enantiomer of tianeptine.

52. The method according to any one of claims 46-51, wherein the tianeptine alkyl ester is a methyl ester, an ethyl ester or any other C1-C6alkyl ester.

53. The method according to any one of claims 46-51, wherein the enantioselective crystallization comprises using a conformer selected from the group consisting of L- dibenzoyl tartaric acid (DBTA), D-DBTA, Di-o-toluoyl-L-tartaric acid (L-D(2-Attorney Docket No.: 104545-0096-WO1 Me)BTA), D-D(2-Me)BTA, other DBTA derivatives, (S)-1,1′-Bi-2-naphthol-2,2′-diyl hydrogen phosphate, (R)-1,1′-Bi-2-naphthol-2,2′-diyl hydrogen phosphate, (S)-(R)- mandelic acid, (R)-(S)-mandelic acid, (S)-(S)-alpha-methoxy-alpha- trifluoromethylphenylacetic acid, (R)-(S)-alpha-methoxy-alpha- trifluoromethylphenylacetic acid, (1S)-(R)-10-camphorsulfonic acid and (1R)-(R)-10- camphorsulfonic acid.

54. The method according to any one of claims 46-51, wherein the solvent comprises a mixture of benzene, acetone and trichloromethane.

55. The method according to any one of claims 46-51, wherein the enantioselective crystallization of the (S)-amine tianeptine intermediate:(S)-enantiomer-selective- conformer, the (S)-amine 11-D-tianeptine intermediate:(S)-enantiomer-selective- conformer, (R)-tianeptine alkyl ester:(R)-enantiomer-selective-conformer or the 11- D-(R)-tianeptine alkyl ester:(R)-enantiomer-selective-conformer comprises the step of slow evaporation of the solvent mixture.

56. The method according to any one of claims 46-55, wherein the enantioselective crystallization is repeated to increase the enantiomeric purity or chiral purity of the resolved (S)-amine tianeptine intermediate, the (S)-amine 11-D-tianeptine intermediate, the (S)-tianeptine methyl ester or 11-D-(S)-tianeptine methyl ester.

57. The method according to any one of claims 46-51, wherein resolving the racemic or other mixture is performed using high performance liquid chromatography (HPLC).

58. The method according to any one of claims 46-51, wherein resolving the racemic or other mixture is performed using supercritical fluid chromatography with a chiral column.

59. A method of treating a disease, disorder or condition selected from the group consisting of a central nervous system (CNS) disorder, inflammatory disease, autoimmune disease, infectious illness, a hearing loss condition, ocular disease, musculoskeletal disease, metabolic disease, mitochondrial disease, hypertriglyceridemia, cancer, menopause and chronic overlapping pain conditionsAttorney Docket No.: 104545-0096-WO1 (COPCs), and psychological, physical, metabolic or hormonal stress and COPCs, comprising administering to a subject in need or at risk thereof a therapeutically effective amount of the (S)-enantiomer, or a co-crystal of the (S)-enantiomer or the zwitterion thereof, or an ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 1-10 and 22, or a pharmaceutical composition according to any one of claims 23, 24 or 27-29 or administering to the subject a therapeutically effective amount of the 11-D-(S)-enantiomer, the zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(S)-enantiomer or a co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or an ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 11-22, or a pharmaceutical composition according to any one of claims 25-29.

60. A method of enhancing neurite outgrowth comprising administering to a subject in need thereof the (S)-enantiomer, or a co-crystal of the (S)-enantiomer or the zwitterion thereof, or an ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 1-10 and 22, or a pharmaceutical composition according to any one of claims 23, 24 or 27-29 or administering to the subject a therapeutically effective amount of the 11-D-(S)-enantiomer, the zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(S)-enantiomer or a co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or an ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 11-22, or a pharmaceutical composition according to any one of claims 25-29.

61. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with excessive levels of metal ions in circulation, comprising administering to a subject in need or at risk thereof a therapeutically effective amount of the (S)-enantiomer, or a co-crystal of the (S)-enantiomer or the zwitterion thereof, or an ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 1-10 and 22, or a pharmaceutical composition according to any oneAttorney Docket No.: 104545-0096-WO1 of claims 23, 24 or 27-29 or administering to the subject a therapeutically effective amount of the 11-D-(S)-enantiomer, the zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(S)-enantiomer or a co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or an ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 11-22, or a pharmaceutical composition according to any one of claims 25-29.

62. A method of reducing violent or aggressive behavior associated with a CNS disorder, comprising administering to a subject in need or at risk thereof a therapeutically effective amount of the (S)-enantiomer, or a co-crystal of the (S)-enantiomer or the zwitterion thereof, or an ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 1-10 and 22, or a pharmaceutical composition according to any one of claims 23, 24 or 27-29 or administering to the subject a therapeutically effective amount of the 11-D-(S)-enantiomer, the zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(S)-enantiomer or a co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or an ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 11-22, or a pharmaceutical composition according to any one of claims 25-29.

63. A method of reducing the potential of being committed to a psychiatric hospital or being incarcerated due to behavior or actions associated with a CNS disorder, comprising administering to a subject in need or at risk thereof a therapeutically effective amount of the (S)-enantiomer, or a co-crystal of the (S)-enantiomer or the zwitterion thereof, or an ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 1-10 and 22, or a pharmaceutical composition according to any one of claims 23, 24 or 27-29 or administering to the subject a therapeutically effective amount of the 11-D-(S)-enantiomer, the zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(S)-enantiomer or a co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or an ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer orAttorney Docket No.: 104545-0096-WO1 pharmaceutically acceptable salt thereof according to any one of claims 11-22, or a pharmaceutical composition according to any one of claims 25-29.

64. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with high levels of S-nitrosylation of PPAR-β / δ and / or PPAR-γ, comprising administering to a subject in need or at risk thereof a therapeutically effective amount of the (S)-enantiomer, or a co-crystal of the (S)-enantiomer or the zwitterion thereof, or an ester of the (S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 1-10 and 22, or a pharmaceutical composition according to any one of claims 23, 24 or 27-29 or administering to the subject a therapeutically effective amount of the 11-D-(S)-enantiomer, the zwitterion thereof, or a pharmaceutically acceptable salt of the 11-D-(S)-enantiomer or a co-crystal of the 11-D-(S)-enantiomer or the zwitterion thereof, or an ester of the 11-D-(S)-enantiomer or pharmaceutically acceptable salt thereof, or an amide of the (S)-enantiomer or pharmaceutically acceptable salt thereof according to any one of claims 11-22, or a pharmaceutical composition according to any one of claims 25-29.

65. N-hydroxy-tianeptine of the Formula (XV) or a pharmaceutically acceptable salt thereof:Formula (XV).

66. The (S)-enantiomer of N-hydroxy-tianeptine (N-hydroxy-(S)-tianeptine) of the Formula (XVI) or a pharmaceutically acceptable salt thereof, wherein the (S)- enantiomer of N-hydroxy-tianeptine or pharmaceutically acceptable salt thereof areAttorney Docket No.: 104545-0096-WO1 characterized by comprising ≤ about 2% of the (R)-enantiomer of N-hydroxy- tianeptine or a pharmaceutically acceptable salt of the (R)-enantiomer of N-hydroxy- tianeptine:Formula (XVI).

67. The (R)-enantiomer of N-hydroxy-tianeptine (N-hydroxy-(R)-tianeptine) of the Formula (XVII) or a pharmaceutically acceptable salt thereof, wherein the (R)- enantiomer, of N-hydroxy-tianeptine or pharmaceutically acceptable salt thereof are characterized by comprising ≤ about 2% of the (S)-enantiomer of N-hydroxy- tianeptine or a pharmaceutically acceptable salt of the (S)-enantiomer of N-hydroxy- tianeptine:Formula (XVII).

68. N-nitroso-tianeptine of the Formula (XVIII) or a pharmaceutically acceptable salt thereof:Attorney Docket No.: 104545-0096-WO169. The (S)-enantiomer of N-nitroso-tianeptine (N-nitroso-(S)-tianeptine) of the Formula (XIX) or a pharmaceutically acceptable salt thereof, wherein the (S)-enantiomer, of N-nitroso-tianeptine or pharmaceutically acceptable salt thereof are characterized by comprising ≤ about 2% of the (R)-enantiomer of N-nitroso-tianeptine or a pharmaceutically acceptable salt of the (R)-enantiomer of N-nitroso-tianeptine:

70. The (R)-enantiomer of N-nitroso-tianeptine (N-nitroso-(R)-tianeptine) of the Formula (XX) or a pharmaceutically acceptable salt thereof, wherein the (R)-enantiomer, of N- nitroso-tianeptine or pharmaceutically acceptable salt thereof are characterized by comprising ≤ about 2% of the (S)-enantiomer of N-nitroso-tianeptine or a pharmaceutically acceptable salt of the (S)-enantiomer of N-nitroso-tianeptine:Attorney Docket No.: 104545-0096-WO171. An aryl substituted tianeptine analog or a pharmaceutically acceptable salt thereof. 7 . The aryl substituted tianeptine analog according to claim 71, wherein the aryl substituted tianeptine derivative is 7-((3-(furan-2-yl)-6-methyl-5,5-dioxido-6,11- dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)heptanoic acid of Formula (XXI), 7- ((3-(furan-3-yl)-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11- yl)amino)heptanoic acid of Formula (XXII), 7-((6-methyl-5,5-dioxido-3-(thiophen-3- yl)-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)heptanoic acid of Formula (XXIII) or 2-(4-(((3-chloro-6-methyl-5,5-dioxido-6,11- dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)methyl)-2-methylphenoxy)acetic acid of Formula (XXIV).Formula (XXIII) Formula (XXIV)Attorney Docket No.: 104545-0096-WO1 73. A pharmaceutical composition comprising the N-hydroxy-tianeptine or a pharmaceutically acceptable salt thereof according to claim 65, or the N-nitroso- tianeptine or a pharmaceutically acceptable salt thereof according to claim 68, or an aryl substituted tianeptine analog or a pharmaceutically acceptable salt thereof according to claim 71 or 72 and a pharmaceutically acceptable carrier, diluent, or excipient.

74. A pharmaceutical composition comprising the (S)-enantiomer of N-hydroxy- tianeptine or a pharmaceutically acceptable salt thereof according to claim 66, or the (S)-enantiomer of N-nitroso-tianeptine or a pharmaceutically acceptable salt thereof according to claim 69 and a pharmaceutically acceptable carrier, diluent, or excipient, wherein the composition comprises ≤ about 2%, or ≤ about 0.1%, of the (R)- enantiomer of N-hydroxy-tianeptine or N-nitroso-tianeptine or pharmaceutically acceptable salt of the (R)-enantiomer of N-hydroxy-tianeptine or N-nitroso-tianeptine or pharmaceutically acceptable salt thereof.

75. A pharmaceutical composition comprising the (R)-enantiomer of N-hydroxy- tianeptine or a pharmaceutically acceptable salt thereof according to claim 67, or the (R)-enantiomer of N-nitroso-tianeptine or a pharmaceutically acceptable salt thereof according to claim 70 and a pharmaceutically acceptable carrier, diluent, or excipient, wherein the composition comprises ≤ about 2%, or ≤ about 0.1%, of the (S)- enantiomer of N-hydroxy-tianeptine or N-nitroso-tianeptine or pharmaceutically acceptable salt of the (S)-enantiomer of N-hydroxy-tianeptine or N-nitroso-tianeptine or pharmaceutically acceptable salt thereof.

76. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with altered activity of peroxisome proliferator-activated receptor (PPAR)-β / δ and / or PPAR-γ and one or more associated symptoms thereof, comprising administering to a subject in need or at risk thereof a therapeutically effective amount of the N-hydroxy-tianeptine, the (S)-enantiomer of N-hydroxy- tianeptine, the (R)-enantiomer of N-hydroxy-tianeptine, or a pharmaceutically acceptable salt of any of them according to anyone of claims 65-67, or the N-nitroso- tianeptine, the (S)-enantiomer of N-nitroso-tianeptine, or the (R)-enantiomer of N-Attorney Docket No.: 104545-0096-WO1 nitroso-tianeptine, or a pharmaceutically acceptable salt of any of them according to anyone of claims 68-70, or an aryl substituted tianeptine analog or a pharmaceutically acceptable salt thereof according to claim 71 or 72 or the pharmaceutical composition according to any one of claims 73-75.

77. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with altered activity of peroxisome proliferator-activated receptor (PPAR)-β / δ and / or PPAR-γ and one or more associated symptoms thereof, in a subject who has experienced high stress, comprising administering to the subject a therapeutically effective amount of the N-hydroxy-tianeptine, the (S)-enantiomer of N-hydroxy-tianeptine, the (R)-enantiomer of N-hydroxy-tianeptine, or a pharmaceutically acceptable salt of any of them according to anyone of claims 65-67, or the N-nitroso-tianeptine, the (S)-enantiomer of N-nitroso-tianeptine, or the (R)- enantiomer of N-nitroso-tianeptine, or a pharmaceutically acceptable salt of any of them according to anyone of claims 68-70, or an aryl substituted tianeptine analog or a pharmaceutically acceptable salt thereof according to claim 71 or 72 or the pharmaceutical composition according to any one of claims 73-75.

78. A method of treating a disease, disorder or condition modulated by, exacerbated by, or associated with altered activity of peroxisome proliferator-activated receptor (PPAR)-β / δ and / or PPAR-γ and one or more associated symptoms thereof, while reducing µ-opioid receptor agonism associated with treatment with racemic tianeptine, comprising administering to a subject in need or at risk thereof a therapeutically effective amount of the N-hydroxy-tianeptine, the (S)-enantiomer of N-hydroxy-tianeptine, the (R)-enantiomer of N-hydroxy-tianeptine, or a pharmaceutically acceptable salt of any of them according to anyone of claims 65-67, or the N-nitroso-tianeptine, the (S)-enantiomer of N-nitroso-tianeptine, or the (R)- enantiomer of N-nitroso-tianeptine, or a pharmaceutically acceptable salt of any of them according to anyone of claims 68-70, or an aryl substituted tianeptine analog or a pharmaceutically acceptable salt thereof according to claim 71 or 72 or the pharmaceutical composition according to any one of claims 73-75.

79. A method of treating a disease, disorder or condition selected from the group consisting of a central nervous system (CNS) disorder, asthma, primary biliaryAttorney Docket No.: 104545-0096-WO1 cholangitis, hypertriglyceridemia, cardiac hypertrophy, fibromyalgia, cancer, infectious illness, COVID-19, long COVID, menopause and chronic overlapping pain conditions (COPCs), psychological, physical, metabolic or hormonal stress and COPCs, and obesity, comprising administering to the subject a therapeutically effective amount of the N-hydroxy-tianeptine, the (S)-enantiomer of N-hydroxy- tianeptine, the (R)-enantiomer of N-hydroxy-tianeptine, or a pharmaceutically acceptable salt of any of them according to anyone of claims 65-67, or the N-nitroso- tianeptine, the (S)-enantiomer of N-nitroso-tianeptine, or the (R)-enantiomer of N- nitroso-tianeptine, or a pharmaceutically acceptable salt of any of them according to anyone of claims 68-70, or an aryl substituted tianeptine analog or a pharmaceutically acceptable salt thereof according to claim 71 or 72 or the pharmaceutical composition according to any one of claims 73-75.

80. A crystalline hemi-oxalate salt of (S)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid 5,5-dioxide ((S)-tianeptine), wherein the salt exhibits an X-ray diffraction pattern (XRPD) comprising at least one peak selected from 8.5, 20.6, 21.0 and 24.2 degrees 2θ ±0.3 degrees 2θ.

81. A crystalline free acid / free base of the (S)-enantiomer of tianeptine according to claim 1, wherein the crystalline (S)-enantiomer of tianeptine exhibits an X-ray diffraction pattern (XRPD) comprising at least one peak selected from 10.6, 13.0, 21.1 and 23.7 degrees 2θ ±0.3 degrees 2θ.